<DOC>
	<DOC>NCT02985398</DOC>
	<brief_summary>An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine</brief_summary>
	<brief_title>An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening. Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening. Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome). Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded. History or diagnosis of complicated migraine (ICHDIII beta version, 20134), chronic tensiontype headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>